Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6228 全譜. Please read: https://finlab.finance/en/setup?stock=6228

No install, open FinLab Studio

6228

全譜 Computer & Peripherals As of 2026-06-17 Updated daily after market close

quality needs a look, premium valuation.

1 active signal

Revenue ≥20%

This page refreshes daily after the close. Add 全譜 to your watchlist to track signal changes on your next visit.

Is 全譜 a buy? Fundamentals and valuation first

Weak profitability.Operating margin is in the 7th market percentile. Latest quarterly ROE ≈ -0.7%.
Valuation is high.PE is in the 97th market percentile.
Foreign investors are net selling.Foreign 20-day net flow ≈ -0.6% of volume (net sell).
Strong revenue growth.Latest monthly revenue YoY ≈ 25.6%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.39

BearishNeutralBullish

Institutional rotation, concentration steady — bullish

Institutional rotation, concentration steady — bullish
美好-中壢 holds 51 lots
sellers have 2 lots left, ~20 sessions to clear

Window from 2026-01-17 · Price -20% · branches to 2026-06-17· TDCC to 2026-06-12

Largest holder 美好-中壢 has accumulated 51 lots since the start (sold 0%), holding.
Main distributor 凱基-大里 peaked at 7 lots, has sold 29%, 5 left, paused recently.
TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +0, retail +0.00pp — little change.
Foreign hedge-desk net short Net short -4 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).

Branch inventory reconstruction

Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.

Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.

Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.

Accumulating

美好-中壢凱基-台南新光元大-松江富邦-永和元大-士林

Distributing

凱基-大里永豐金證券元大-大天母兆豐-彰化凱基-三重富邦-板橋

Desks

own scale

國票-台東華南永昌-台南玉山-城中中國信託-文心

Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline

Branch details Unit: lots

Accumulating

美好-中壢 +51

sold 0%
凱基-台南 +44

sold 0%
新光 +39

sold 0%
元大-松江 +28

sold 0%· still adding
富邦-永和 +24

sold 0%
元大-士林 +23

sold 0%

Distributing

凱基-大里 5 left

sold 29%· paused recently
永豐金證券 3 left

sold 57%· paused recently
元大-大天母 3 left

sold 40%· paused recently
兆豐-彰化 3 left

sold 25%· paused recently
凱基-三重 1 left

sold 75%· paused recently
富邦-板橋 2 left

sold 33%· ~20 sessions to clear

Desks

國票-台東 -46

unclassified
華南永昌-台南 -42

unclassified
玉山-城中 -38

unclassified
中國信託-文心 -20

unclassified

Still selling 2 lots ~20 sessions to bottom at most

Recent buy/sell force +61 absorbed / -1 sold buyers slightly ahead

TDCC big holders · absolute-holding cross-check

>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 25.55%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

102 historical occurrences (since 2007-04-23)

120 days after: historical avg +6.97%

20-day +3.2%

60-day +11.01%

120-day +6.97%

20-day

60-day

120-day

Win

47.3%

53.3%

43.3%

Sample

Median

-0.93%

+2.23%

-5.53%

Excess

+2.45%

+6.6%

+0.12%

Beat mkt rate

40.9%

43.5%

37.8%

Over 90 occurrences, 120-day forward avg gained 6.97%, beat the market by 0.12 pts; win rate 43.3%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

16 times historically; 60-day forward avg +9.9%, win rate 62.5%, beating the market by +7.11 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

10 times historically; 60-day forward avg -1.92%, win rate 40%, beating the market by -7.25 pts on average.

What does 全譜 do? Company profile

電腦及週邊設備業上櫃（櫃買中心/TPEX）

Overview

6228 對應證券為全譜科技股份有限公司，為櫃買中心上櫃普通股，非 ETF/ETN/權證。公司成立於 1993/09/20，1997/05/08 公開發行，2002/08/02 興櫃，2003/01/21 上櫃。總公司與工廠位於新北市汐止區大同路一段239號7樓，另有美國子公司 Pacific Image Electronics Inc.，位於美國加州 Torrance，負責美國市場銷售、售後服務、倉儲與應收帳款催收。董事長高偉超，總經理曾治元，財務長/發言人陳素花。實收資本額新台幣260,000,000元，已發行普通股26,000,000股。115年3月31日員工27人，平均年齡49.3歲、平均服務年資11.74年；研發人員7人。115年3月31日前十大股東包括三德觀光大飯店股份有限公司14,543,947股、持股55.94%，三德投資股份有限公司2,012,063股、持股7.74%，葉語柔3.16%，杜逸嵐3.16%，杜逸塵3.16%，偉佳投資2.94%，高偉超2.33%，趙懌寧2.00%，吳振益1.15%，吳貞儀0.88%。公司簽證會計師為勤業眾信聯合會計師事務所。

Business

全譜以影像掃描與光學/生醫檢測平台為核心，主要經營底片型掃瞄器、生物醫學產品、ODM/OEM 影像分析儀器，以及少量建材及工程業務。114年度合併營收淨額新台幣51,271仟元，年增19.96%，稅後淨損12,129仟元；產品別營收為底片型掃瞄器30,279仟元、占59.06%，生物醫學產品20,989仟元、占40.94%，建材及工程3仟元、約0%。銷售地區以外銷為主：114年度美洲20,322仟元、39.64%，歐洲12,761仟元、24.89%，亞洲13,678仟元、26.67%，內銷4,510仟元、8.80%。底片掃描器產品包括 PrimeFilm/PowerFilm/PowerSlide 等系列，用於135、120底片或幻燈片數位化；生醫產品包括 Glite/Slite/ChemLux 凝膠影像分析系統、RapidScan 快檢讀取儀、bHome Reader、POCT/側向層析與生化試驗讀取平台、陣列影像平台等。商業模式為自有品牌 OBM、ODM/OEM、代工/貼牌並行；成熟市場如歐美以底片掃描器自有品牌及生醫儀器 ODM/貼牌切入，新興市場如亞太、中東則推自有品牌。公司表示曾為 Kodak、KIS 等品牌提供設計與製造服務；近年生醫策略由研發市場切入，再延伸至食品安全、環境監測、寵物檢測、毒品檢測、人醫檢測、傳染病篩檢與家用檢測。114年度銷貨占10%以上客戶以匿名 A、B、C、D 公司揭露，分別約占21.55%、19.53%、17.30%、15.82%，未揭露實名。

Outlook 2025–2028

2025年（民國114年）已呈現營收回升但仍虧損：合併營收51,271仟元、年增19.96%，每股稅後盈餘-0.47元，虧損較113年度收斂。2026年（民國115年）公司營運重點為：底片掃描器 Plus 系列全面上市後強化全球行銷、鞏固美國並拓展歐洲代理及線上通路；生醫產品聚焦高成長生物檢測市場，已完成專業檢驗室、戶外現場 POCT 與居家小型讀取機台布局，並將資源集中於 Glite T8、RapidScan PH/PH+、RapidScan ST5、M-Reader、雲端資料庫、AI 判讀與 ODM 客製化案。公司預估115年度銷售量：底片掃描器美洲800台、歐洲900台、其他120台；生醫產品包括小型凝膠成像系統200台、螢光凝膠成像系統10台、化學冷光螢光影像系統35台、玻片掃瞄儀120台、快檢讀取儀1000台。2027-2028年展望屬推估：若快檢讀取儀由食安、環境、寵物、毒品檢測順利滲透至人醫、診所與家用場景，且透過 OEM/ODM 與試片供應商策略聯盟形成耗材經濟，公司有機會從硬體銷售轉向完整檢測價值鏈系統供應商；底片掃描器則偏利基長尾市場，重點在提升毛利與現金流而非高速成長。主要風險包括：公司規模小、營收基期低且仍虧損；生醫市場需通路、認證、試劑夥伴與臨床場景理解，商用化不確定性高；國際大廠在 GDS/POCT 市場品牌與通路優勢明顯；主要客戶匿名且集中度高；外銷占比高，美元與歐元匯率波動會影響損益；建材及工程受台灣房市信用管制、缺工缺料、營建成本上升影響，公司採保守態度。

Supply Chain

Upstream

IC、光學感測器與機構件供應商年報揭露掃描器部分 IC 與機構類零件有國外進口，供應商眾多且未揭露實名；屬電子零組件、CCD/CMOS、光學、機構與傳動元件供應來源。
試片與生物試劑合作夥伴公司明確表示不直接投入生物試劑研發，長期將透過策略結盟把試片供應商轉為合作夥伴；實名未揭露，包含第三方檢測實驗室、寵物診斷試劑廠及試劑開發商等非公開或海外機構。
建材供應商建材及工程業務上游包括鋼筋、混凝土、磁磚、地磚、衛浴等供應商；公司稱國內外供應商眾多、未揭露實名。
A公司、B公司 114年度進貨占10%以上供應商以匿名揭露；A公司進貨1,883仟元、占16.20%，B公司1,396仟元、占12.01%，與發行人關係均為無，未揭露是否上市櫃。

Downstream

Pacific Image Electronics Inc.（美國子公司）全譜100%持股美國子公司，位於加州 Torrance，負責美國市場業務開發、銷售、售後服務、倉儲與應收帳款催收；非台股掛牌。
Kodak 公司官網稱曾為 Kodak 等大型品牌提供設計與製造服務；海外品牌，非台股掛牌。
KIS 公司官網稱曾為 KIS 等大型品牌提供設計與製造服務；海外品牌，非台股掛牌。
A公司、B公司、C公司、D公司 114年度銷貨占10%以上客戶以匿名揭露：A公司11,048仟元、21.55%；B公司10,015仟元、19.53%；C公司8,871仟元、17.30%；D公司8,113仟元、15.82%；與發行人關係均為無，未揭露實名與掛牌狀態。
全球代理商、線上通路、檢驗中心、基層診所、家用檢測市場下游應用與通路包括底片掃描器歐美代理與線上銷售、生醫 ODM/OEM 客戶、研究實驗室、食品安全/環境/寵物/毒品檢測、人醫檢測、診所與家用檢測；多數未揭露個別公司名稱。

Competitors

Bio-Rad Laboratories 全球生物試劑與儀器商；全譜年報列為螢光與化學光成像系統主要競爭者，推估市占約36%；美國上市，非台股掛牌。
Thermo Fisher Scientific 全球生物研究儀器設備商；年報列為 GDS 競爭者，推估市占約20%；美國上市，非台股掛牌。
GE Healthcare / Cytiva 年報列為全球生物研究儀器設備商與 GDS 競爭者，推估市占約20%；非台股掛牌。
Analytik Jena 年報列為美國凝膠成像系統領導品牌，推估市占約10%；非台股掛牌。
ATTO 年報列為日本凝膠成像系統廠商，推估市占約5%；非台股掛牌。
Syngene 年報列為英國凝膠成像系統品牌，推估市占約5%；非台股掛牌。
Azure Biosystems 年報列為美國凝膠成像系統新進自有品牌，推估市占約3%；非台股掛牌。
Abbott 年報列為 POCT 市場全球領先者，與自產試劑高度綁定；美國上市，非台股掛牌。
QuidelOrtho 年報列為螢光免疫分析與雲端連網定量市場重要競爭者；美國上市，非台股掛牌。
BD（Becton Dickinson）年報列為診所端 POCT 具高占有率廠商；美國上市，非台股掛牌。
Qiagen 年報列為專業實驗室與高階分子診斷競爭者；歐洲/美國上市，非台股掛牌。
Axxin 年報列為全球平台型 POCT reader 代工商，為多家試劑廠提供客製化 reader 方案；非台股掛牌。
Wondfo（萬孚生物）年報列為亞太與新興市場成長快速、具價格競爭力之 POCT 競爭者；中國上市，非台股掛牌。
Seiko Epson 底片/文件掃描器與影像輸出設備國際品牌，屬掃描器產品線潛在競爭者；日本上市，非台股掛牌。
Plustek（精益科技）台灣掃描器品牌，屬底片掃描器/影像掃描產品競爭者；未確認台股上市櫃，故 stock_id 設 null。
Microtek（全友電腦） 2305 台股上市掃描器與影像擷取相關公司，屬掃描器領域可比競爭者；與全譜產品、市場重疊程度需另以產品線確認。

Sources（13）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
Excess return is measured against the TAIEX total-return index (dividends included).
Valuation regime and percentile stats use an expanding own-history window (no future data).
Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.